Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure

Clinical and Experimental Nephrology

Volumn 10, Issue 3, 2006, Pages 201-209

  Saltissi, David ^a   Westhuyzen, Justin ^a,b   Morgan, Colleen ^a   Healy, Helen ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Atorvastatin; Cholesterol; Continuous ambulatory peritoneal dialysis; Hemodialysis; Hyperlipidemia; Triglycerides

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATINE KINASE; FISH OIL; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; POTASSIUM; TRIACYLGLYCEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGY; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOOT PAIN; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG PAIN; LIMB PAIN; MALE; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; MYALGIA; PATIENT COMPLIANCE; PRURITUS; THERAPY EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROSPECTIVE STUDIES; PYRROLES; RENAL DIALYSIS; TRIGLYCERIDES;

EID: 33749334910     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-006-0425-8     Document Type: Article

References (51)

1. JH Brown LP Hunt NP Vites CD Short R Gokal NP Mallick 1994 Comparative mortality from cardiovascular disease in patients with chronic renal failure Nephrol Dial Transplant 9 1136 42
2. M Sentí R Romero J Pedro-Botet A Pelegri X Nogues J Rubiés-Prat 1992 Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on dialysis with chronic renal failure Kidney Int 41 1394 9
3. P-O Attman P Alaupovic 1991 Lipid abnormalities in chronic renal insufficiency Kidney Int 39 Suppl 31 S16 23
4. PO Attman P Alaupovic 1991 Lipid and apolipoprotein profiles of uremic dyslipoproteinemia - relation to renal function and dialysis Nephron 57 401 10
5. C Wanner V Krane W Marz M Olschewski JF Mann G Ruf 2005 Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis New Engl J Med 353 238 48
6. C Baigent M Landry 2003 Study of Heart and Renal Protection (SHARP) Kidney Int Suppl 84 S207 10
7. BC Fellstrom H Holdaas AG Jardine 2003 Why do we need a statin trial in hemodialysis patients? Kidney Int Suppl 84 S204 6
8. D Saltissi C Morgan RJ Rigby J Westhuyzen 2002 Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis Am J Kidney Dis 39 283 90
9. SL Seliger CO Stehman-Breen 2003 Are HMG-CoA reductase inhibitors underutilized in dialysis patients? Semin Dial 16 179 85
10. LA Simons 1998 Comparison of atorvastatin alone versus simvastatin ± cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study) Aust N Z J Med 28 327 33
11. BH Wolffenbuttel G Mahla D Muller A Pentrup DM Black 1998 Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia Neth J Med 52 131 7
12. DG Karalis AM Ross RM Vacari H Zarren R Scott 2002 Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease Am J Cardiol 89 667 71
13. MR Law NJ Wald AR Rudnicka 2003 Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 1423 9
14. RC Ozsoy JJ Kastelein L Arisz MG Koopman 2003 Atorvastatin and the dyslipidemia of early renal failure Atherosclerosis 166 187 94
15. JF Navarro C Mora M Muros G Garcia-Idoate 2003 Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis Nephron Clin Pract 95 c128 35
16. JM van der Akker SJ Bredie SH Diepenveen LJ Van Tits AF Stalenhoef R Van Leusen 2003 Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidised LDL J Nephrol 16 238 44
17. A Ikejiri T Hirano S Murayama G Yoshino N Gushiken T Hyodo 2004 Effect of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients Metabolism 53 1113 7
18. RL Lins KE Matthys JM Billiouw M Dratwa P Dupont NH Lameire 2004 Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study Clin Nephrol 62 287 94
19. KA Doornbrook-Lavender MS Joy CJ Denu-Ciocca H Chin SL Hogan JA Pieper 2005 Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing lone-term dialysis Pharmcotherapy 25 335 44
20. G Hufnagel C Michel F Vrtovsnik G Queffeulou N Kossari F Mignon 2000 Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis Nephrol Dial Transplant 15 684 8
21. KP Harris DC Wheeler CC Chong 2002 AtorvastatIn in CAPD Study Investigators. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD Kidney Int 61 1469 74
22. National Heart Foundation, Diet and Heart Disease Advisory Committee. Guide to plasma lipids for doctors. National Heart Foundation. Sydney; Australia; September 1995
23. cr) (abstract) Kidney Int 40 561 2
24. A Bofinger J Westhuyzen D Saltissi C Morgan H Healy 1997 Low-density lipoprotein subfraction profiles in patients with end-stage renal disease treated with haemodialysis or peritoneal dialysis Nephrology 3 169 76
25. C Wanner J Bohler G Eckardt H Wieland P Schollmeyer 1994 Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephritic syndrome Clin Nephrol 41 138 43
26. MM Prata AC Noguiera JR Pinto AM Correia O Vicente MC Rodrigues 1994 Long-term effect of lovastatin on lipoprotein profile in patients with primary nephritic syndrome Clin Nephrol 41 277 83
27. E Matthys M Schurgers G Lamberigts N Lamiere N Vandecasteele 1991 Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients Atherosclerosis 86 183 92
28. P Li TWL Mak K Chiu CB Leung SF Lui CWK Lam 1992 Effect of lovastatin on serum lipid profile in renal failure patients on continuous ambulatory peritoneal dialysis (abstract) Clin Biochem Rev 13 112
29. R Marangoni F Civardi F Masi R Cimino L Maltagliati G Romei Longhena 1993 Dislipemia in patients undergoing continuous ambulatory peritoneal dialysis: pharmacological therapy (simvastatin) versus hemodialysis Perit Dial Int 13 Suppl 2 S431 3
30. Y Nishizawa T Shoji H Nishitani M Yamakawa T Konishi K Kawasaki 1993 Hypertriglyceridemia and lowered apolipoprotein C-II/C/III ratio in uremia: effect of a fibric acid, clinofibrate Kidney Int 44 1352 9
31. HM Colhoun DJ Bettridge PN Durrington GA Hitman HA Neil SJ Livingstone 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 685 96
32. R Agarwal T Curley 2005 The role of statins in chronic kidney disease Am J Med Sci 330 69 81
33. V Melenovsky J Malik D Wichterle J Simek A Pisarikova J Skrha 2002 Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and LDL particle size in subjects with combined hyperlipidemia Am Heart J 144 E6
34. H Jansen W Hop A van Tol AV Bruschke JC Birkenhager 1994 Hepatic lipase and lipoprotein lipase are not major determinants of the low density lipoprotein subclass pattern in human subjects with coronary heart disease Atherosclerosis 107 45 54
35. JR McNamara JL Jenner Z Li PW Wilson EJ Schaefer 1992 Change in LDL particle size is associated with change in plasma triglyceride concentration Arterioscler Thromb 12 1284 90
36. M Lariviere B Lamarche M Pirro JC Hogue J Bergeron C Gagne 2003 Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia Atherosclerosis 167 97 104
37. MJ Stampfer RM Krauss J Ma PJ Blanche LG Holl FM Sacks 1996 A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction JAMA 276 882 8
38. N Hoogerbrugge H Jansen 1999 Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia Atherosclerosis 146 167 74
39. K Berneis M Rizzo 2004 LDL size: does it matter? Swiss Med Wkly 134 720 4
40. E Hurt-Camejo G Camejo P Sartipy 2000 Phospholipase A2 and small, dense low-density lipoprotein Curr Opin Lipidol 11 465 71
41. CR Sirtori L Calabresi L Pisciotta L Cattin P Pauciullo M Montagnani 2005 Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin Nutr Metab Cardiovasc Dis 15 47 55
42. O Wiklund L Mattsson-Hulten E Hurt-Camejo J Oscarsson 2002 Effects of simvastatin and atorvastatin on inflammation markers in plasma J Intern Med 251 338 47
43. L Pontrelli W Parris K Adeli RC Cheung 2002 Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes Metabolism 51 334 42
44. RL Lins KE Matthys GA Verpooten PC Peeters M Dratwa JC Stolear 2003 Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients Nephrol Dial Transplant 18 967 76
45. JY Yeun GA Kaysen 1998 Factors influencing serum albumin in dialysis patients Am J Kidney Dis 32 6 Suppl 4 S118 25
46. S Beddhu GA Kaysen G Yan M Sarnak L Agodoa D Ornt AK Cheung HEMO Study Group 2002 Association of serum albumin and atherosclerosis in chronic hemodialysis patients Am J Kidney Dis 40 721 7
47. F Bernini A Poli R Paoletti 2001 Safety of HMG-CoA reductase inhibitors: focus on atorvastatin Cardiovasc Drugs Ther 15 211 8
48. HS Malhotra KL Goa 2001 Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia Drugs 61 1835 81
49. RG Bakker-Arkema MH Davidson RJ Goldstein J Davignon JL Issaacsohn SR Weiss 1996 Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patient with hypertriglyceridemia JAMA 275 128 33
50. KY Wang CT Ting 2001 A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10-mg) in patients with elevated LDL-cholesterol Jpn Heart J 42 725 38
51. VG Athyros AA Papageorgiou BR Mercouris VV Athyrou AN Symeonidis EO Basayannis 2002 Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study Curr Med Res Opin 18 220 8